Clinical Trial Update: A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluating CT0596 in relapsed/refractory multiple myeloma and relapsed/refractory plasma cell leukemia is currently recruiting a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• CT0596

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Relapsed/Refractory Plasma Cell Leukemia, Relapsed/Refractory Multiple Myeloma | EARLY_Phase 1 | Status: RECRUITING